NEW YORK — Aspira Women's Health this week reported that revenues for the second quarter slipped 4 percent to $2.4 million from $2.5 million a year ago. The Austin, Texas-based developer of gynecological disease diagnostics reported a net loss of $3.5 million, or $.28 per share, for the recently completed quarter compared to a net loss of $2.3 million, or $.28 per share, a year ago. Aspira increased its R&D spending 37 percent year over year to $952,000 from $693,000 and decreased its SG&A spending 6 percent to $4.9 million from $5.2 million. It ended Q2 with $962,000 in cash and cash equivalents.
Trinity Biotech said this week that its revenues for the second quarter rose 14 percent year over year. For the three months ended June 30, the Dublin-based developer of diagnostics and diabetes management products posted $15.8 million in revenues compared to $13.9 million in Q2 2023. Trinity had a net loss of $6.8 million, or $.71 per ADS, for Q2 2024 compared to a net loss of $6.0 million, or $.78 per ADS, for Q2 2023. Its R&D spending dropped 17 percent to $991,000 in the recently completed quarter from $1.2 million a year ago, while its SG&A costs dropped 19 percent to $6.4 million from $7.9 million. The company also recorded restructuring costs of $1.9 million in Q2 2024 compared to none a year ago. Trinity finished the quarter with $5.3 million in cash, cash equivalents, and deposits.
Quest Diagnostics this week said its board has declared a quarterly dividend of $.75 per share, payable on Oct. 21 to shareholders of record on Oct. 4.
VolitionRx this week announced financial results for the second quarter of 2024, reporting that its overall revenues rose 83 percent to $396,000 from $216,000 in Q2 2023. The Henderson, Nevada-based company sold more than 60,000 of its Nu.Q Vet Cancer tests in the first half of 2024, up from 58,000 in full-year 2023. The firm saw a net loss of $7.1 million, or $.08 per share, compared to a loss of $9.6 million, or $.14 per share, in the year-ago quarter. VolitionRx ended the quarter with $6.0 million in cash and cash equivalents.
DNANudge said this week that it has partnered with Holland & Barrett, a health and wellness retailer in the UK. Under the exclusive agreement, DNANudge will offer its Express DNA test on a trial basis at selected Holland & Barrett stores, providing customers results within 20 minutes via email or mobile app. The test, which uses DNANudge's lab-in-cartridge and NudgeBox technology, sells for £30 ($39) and looks for genetic traits related to oxidative stress on the skin and caffeine metabolism. It is an adaptation of DNANudge's full Nutrition Nudge and Skincare Nudge tests. Based on the results, Holland & Barrett will recommend specific products to customers, such as skincare products.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.